Archive for July, 2009

House Passes Bill Shifting PTO Revenue

July 8, 2009

uspto_sealI previously reported that the Senate was considering a bill to permit the patent side of the PTO to “borrow” money from the trademark side.

Yesterday, the US House of Representatives passed H.R. 3114, which permits the PTO to use up to $70 million in surplus funds from trademark operations to fund the patent side.  The authority of the PTO Director to use these funds lasts until June 30, 2011, and the funds must be repaid to the trademark side by September 30, 2014.  To aid the patent side of the operations in repaying the “loan,” the Director may establish a surcharge on patent fees.

This bill was passed to help the PTO avoid patent examiner furloughs and lay-offs.  If filings continue to decrease, however, it is doubtful that this will be sufficient to sustain patent operations into FY2010.

The other problem is that trademark filings are also way down, with some reports indicating that filings are 10-20% less than for the previous fiscal year.  This means that the trademark side’s well-managed surplus is now being raided for use by the patent side.  This could potentially put the trademark examining attorneys at risk for furloughs and lay-offs.  Which side should bear the risk?

I understand that the money has to come from somewhere, but the PTO’s budget crisis is a result of a significant decrease in filings.  Much of this is the result of the economy, but it is also a result of the PTO’s anti-patent stance with reduced allowance rates and numerous new proposed or implemented rules that make life more difficult for applicants.  An increase in the cost of applying for a patent in the form of a surcharge is not going to increase filings by already cash-strapped companies.

Federal Circuit to Hear PTO Rules Appeal En Banc

July 6, 2009

The entire Federal Circuit has agreed to rehear the PTO appeal in Tafas v. Doll over the PTO’s rule-making authority.  A Federal Circuit panel decided in March that the PTO did have the authority to limit the number of claims in patent applications, but its proposed limitations on the number of continuation applications that can be filed conflicted with the patent statute and was invalid.

This seems to be a surprising turn of events given the current status of the proceedings.  Hopefully, the Federal Circuit will take a much closer look at the PTO’s rule-making authority and the implications of any new rules on patent practice.

Jury Awards Johnson & Johnson Subsidiary $1.67 Billion

July 2, 2009

In an infringement suit in the Eastern District of Texas, Johnson & Johnson subsidiary Centocor, Inc., was awarded $1.67 billion in infringement damages.  The jury found that Abbott Laboratories’ arthritis drug, Humira® (adalimumab), infringed U.S. Patent No. 7,070,775, owned jointly by Centocor and NYU, and that the infringement was willful.  Humira® competes with Centocor’s own arthritis drug, Remicade® (infliximab).

After a trial that lasted a single week, the jury took less than a day to award Centocor lost profit damages of $1,168,466,000 and reasonable royalty damages of $504,128,000.  Double recovery of both lost profits and reasonable royalties is generally not allowed in infringement cases, but sometimes a hybrid of the two may be awarded as damages if, for example, lost profits are difficult to prove.  In this case, it appears that the jury verdict form would allow for both if only a portion of the lost profits could be proven.  Doubtless, this potential ambiguity will be part of the post-trial motions filed in this case.

This infringement verdict may be the largest ever awarded for a patent infringement case.  It should be noted, however, that Abbott launched Humira® in 2002 and its 2008 sales of the drug topped $4.5 billion or about 15% of the company’s total revenue, while sales of Remicade® topped $3.75 billion. 

Both J&J and Abbott have been lobbying against limitations on damage awards for infringement verdicts in the current patent reform debate.  Many earlier high infringement verdicts have been overturned in post-trial motions or on appeal, including the $1.52 billion verdict awarded to Alcatel-Lucent against Microsoft in 2007 over digital music patents.  Judge Ward will shortly entertain such post-trial motions in this case.  These mechanisms seem to be effective for curbing unwarranted damage verdicts.


Follow

Get every new post delivered to your Inbox.